Compare Invesco Ltd. (IVZ) vs Medpace Holdings Inc (MEDP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Invesco Ltd. vs Medpace Holdings Inc — how do they compare? Invesco Ltd. trades at $30.5 (market cap $13.34B), while Medpace Holdings Inc trades at $528.16 (market cap $15.18B). The key difference: Invesco Ltd. and Medpace Holdings Inc are close in size by market cap, and Invesco Ltd. pays a 2.86% dividend while Medpace Holdings Inc pays none. Which is the better fit depends on your goals.
| IVZ | MEDP | |
|---|---|---|
Market Cap | $13.34B | $15.18B |
Sector | Financials | Technology |
52-Week High | $30.30 | $620.59 |
52-Week Low | $20.45 | $393.42 |
Enterprise Value | $23.59B | $14.65B |
Dividend Yield | 2.86% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Invesco (IVZ) trades at $30.10, up 1.59% with a bullish technical outlook supported by moving averages. The company reported mixed Q1 2026 earnings, missing estimates after two consecutive beats. While revenue has grown to $6.38 billion in 2025, net income remains negative at -$281.7 million, though improving from 2023 lows. Analyst consensus shows 42.9% buy ratings with a $30.64 price target, slightly above current levels.
IVZ presents a balanced risk-reward profile with improving operational cash flow ($1.53B in 2025) and positive earnings momentum offset by persistent negative profitability metrics. The stock's valuation appears reasonable with P/E of 19.48 and P/B of 1.35, but investors face execution risks amid competitive asset management pressures and macroeconomic sensitivity.
MEDP trades at $527.93, down 1.82% on the day, with a neutral technical signal and mixed oscillators. The stock shows strong profitability with a 17.19% net margin and 77.25% ROE, though valuations are elevated with a P/E of 33.22. Recent quarters have consistently beaten EPS estimates, but a class action lawsuit filed in June 2026 adds uncertainty. Revenue is projected to grow to $2.7B in 2026, while cash flow trends improve from negative to positive net cash flow.
The outlook is cautious due to high valuation and legal overhangs, but fundamental strength in earnings and backlog quality provides support. Analyst consensus is mixed with a $497 price target below current levels, indicating limited near-term upside. Key risks include lawsuit outcomes and competitive pressures in the CRO sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Invesco Ltd.
Invesco provides investment-management services to retail (65% of managed assets) and institutional (35%) clients. At the end of August 2022, the firm had $1.416 trillion in assets under management spread among its equity (47% of AUM), balanced (5%), fixed-income (22%), alternative investment (14%), and money market (12%) operations. Passive products account for 32% of Invesco's total AUM, including 56% of the company's equity operations and 13% of its fixed-income platform. Invesco's U.S. retail business is one of the 10 largest nonproprietary fund complexes in the country. The firm also has a meaningful presence outside the U.S., with close to one third of its AUM sourced from Canada (2%), the U.K. (4%), continental Europe (11%), and Asia (15%).
Read more on IVZ →About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →
